Wednesday 26 June 2024

NEU Phase 2 trial shows significant improvements

Neuren Pharmaceuticals (ASX:NEU) announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome. Significant improvement was observed by both clinicians and caregivers from treatment | ASX announcement: #shorts

Free stock updates

Subscribe to receive the latest stock news, CEO interviews, expert insights, events and offers directly into your inbox